• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for VYONDYS 53 issued to SAREPTA THERAPS INC

    6/5/24 4:41:31 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SRPT alert in real time by email
    New Drug Application (NDA): 211970
    Company: SAREPTA THERAPS INC
    • Email

    Products on NDA 211970

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    VYONDYS 53 GOLODIRSEN 100MG/2ML (50MG/ML) SOLUTION;INTRAVENOUS Prescription None Yes Yes

    Approval Date(s) and History, Letters, Labels, Reviews for NDA 211970

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    12/12/2019 ORIG-1 Approval Type 1 - New Molecular Entity PRIORITY; Orphan Label (PDF)
    Letter (PDF)
    Review
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211970s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/211970Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211970Orig1s000TOC.cfm
    Supplements
    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
    06/04/2024 SUPPL-11 Labeling-Package Insert

    Label is not available on this site.

    06/04/2024 SUPPL-10 Labeling-Package Insert

    Label is not available on this site.

    02/11/2021 SUPPL-2 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211970s002lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/211970Orig1s002ltr.pdf

    Labels for NDA 211970

    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
    Patient Package Insert
    Note Url
    02/11/2021 SUPPL-2 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211970s002lbl.pdf
    12/12/2019 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211970s000lbl.pdf
    Get the next $SRPT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SRPT

    DatePrice TargetRatingAnalyst
    6/20/2025Outperform → Mkt Perform
    William Blair
    6/18/2025$24.00Buy → Hold
    TD Cowen
    6/17/2025Peer Perform
    Wolfe Research
    6/16/2025Overweight → Equal-Weight
    Morgan Stanley
    6/16/2025Overweight → Neutral
    Cantor Fitzgerald
    6/16/2025Buy → Neutral
    BofA Securities
    6/16/2025$70.00Outperform → Market Perform
    BMO Capital Markets
    6/16/2025$36.00Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $SRPT
    SEC Filings

    See more
    • Sarepta Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Sarepta Therapeutics, Inc. (0000873303) (Filer)

      6/6/25 4:30:31 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Sarepta Therapeutics Inc.

      10-Q - Sarepta Therapeutics, Inc. (0000873303) (Filer)

      5/6/25 4:01:26 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Sarepta Therapeutics Inc.

      DEFA14A - Sarepta Therapeutics, Inc. (0000873303) (Filer)

      4/24/25 4:10:03 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Barry Richard exercised 12,350 shares at a strike of $32.63, increasing direct ownership by 0.42% to 2,966,667 units (SEC Form 4)

      4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

      5/19/25 7:32:14 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Barry Richard exercised 20,246 shares at a strike of $19.23, increasing direct ownership by 0.69% to 2,954,317 units (SEC Form 4)

      4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

      5/15/25 7:00:11 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Nicaise Claude exercised 9,746 shares at a strike of $25.18 and sold $248,203 worth of shares (2,491 units at $99.64), increasing direct ownership by 35% to 27,812 units (SEC Form 4)

      4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

      3/13/25 8:00:04 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sarepta Therapeutics downgraded by William Blair

      William Blair downgraded Sarepta Therapeutics from Outperform to Mkt Perform

      6/20/25 7:52:50 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sarepta Therapeutics downgraded by TD Cowen with a new price target

      TD Cowen downgraded Sarepta Therapeutics from Buy to Hold and set a new price target of $24.00

      6/18/25 7:45:18 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on Sarepta Therapeutics

      Wolfe Research initiated coverage of Sarepta Therapeutics with a rating of Peer Perform

      6/17/25 7:51:08 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SRPT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Chambers Michael Andrew bought $4,955,728 worth of shares (37,038 units at $133.80) (SEC Form 4)

      4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

      8/20/24 8:00:04 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Barry Richard bought $3,940,500 worth of shares (50,000 units at $78.81) (SEC Form 4)

      4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

      11/6/23 8:00:11 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ingram Douglas S bought $2,001,800 worth of shares (25,225 units at $79.36), increasing direct ownership by 7% to 390,307 units (SEC Form 4)

      4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

      11/6/23 8:00:10 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care